Tyra Biosciences, Inc.
TYRA · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.53 | -1.64 | -0.51 |
| FCF Yield | -4.16% | -4.62% | -2.39% | -1.30% |
| EV / EBITDA | -15.25 | -14.42 | -24.75 | -45.18 |
| Quality | ||||
| ROIC | -10.21% | -9.66% | -8.51% | -7.76% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.75 | 0.84 | 0.90 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 6.91% | -29.99% | -9.17% | -67.32% |
| Safety | ||||
| Net Debt / EBITDA | 2.95 | 2.98 | 2.90 | 3.43 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,443.21 | -1,573.43 | 362.90 | -825.59 |